Enhancement of spin-wave nonreciprocity in magnonic crystals via synthetic antiferromagnetic coupling by Piramanayagam, Seidikkurippu Nellainayagam, Zhang, V. L., Lim, H. S., Ng, S. C., Kuok, M. H., Di, K., Feng, S. X.

Get full text
Get full text

Enhancement of skyrmion density via interface engineering by Bhatti, Sabpreet, Tan, H.K., Sim, M.I., Zhang, V. L., Sall, M., Xing, Z. X., Juge, R., Mahendiran, R., Soumyanarayanan, A., Lim, S. T., Ravelosona, D., Piramanayagam, S. N.

Get full text

Synchronization between remote sites for the MINOS experiment by Römisch, S, Jefferts, SR, Zhang, V, Parker, T, Ashby, N, Adamson, P, Barr, G, Habig, A, Meier, J, James, C, Nicol, R, Plunkett, R, Rosenfeld, C, Bumgarner, R, Christensen, M, Hirschauer, J, Fonville, B, Mitchell, S, McKinley, A, Powers, E, Wright, J, Matsakis, D

Safety and Clinical Activity of Mutant IDH1 Inhibitor IVOSIDENIB (IVO; AG-120) In Combination with AZACITIDINE (AZA) for Newly Diagnosed Acute Myeloid Leukemia (ND AML) by DiNardo, C, Stein, A, Stein, E, Fathi, A, Frankfurt, O, Schuh, A, Doehner, H, Martinelli, G, Patel, P, Raffoux, E, Tan, P, Zeidan, A, De Botton, S, Kantarjian, H, Stone, R, Lam, D, Wang, X, Gong, J, Kapsalis, S, Hickman, D, Zhang, V, Winkler, T, Wu, B, Vyas, P

Mutant isocitrate dehydrogenase 1 inhibitor ivosidenib in combination with azacitidine for newly diagnosed acute myeloid leukemia by DiNardo, CD, Stein, AS, Stein, EM, Fathi, AT, Frankfurt, O, Schuh, AC, Döhner, H, Martinelli, G, Patel, PA, Raffoux, E, Tan, P, Zeidan, AM, de Botton, S, Kantarjian, HM, Stone, RM, Frattini, MG, Lersch, F, Gong, J, Gianolio, DA, Zhang, V, Franovic, A, Fan, B, Goldwasser, M, Daigle, S, Choe, S, Wu, B, Winkler, T, Vyas, P